A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer

NCT03027284 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

19

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Cancer
Metastatic Cancer
Biliary Tract Carcinoma
Cholangiocarcinoma
Gall Bladder Carcinoma
Solid Tumor
Non-Hodgkin's Lymphoma

Interventions

DRUG: Merestinib
DRUG: Cisplatin
DRUG: Gemcitabine

Sponsor

Eli Lilly and Company